MedTrace Logo

Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer

NCT01563796 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1115

Last updated 2025-09-26

No results posted yet for this study

Summary

The objective of this study is to use a DEK ELISA to quantitatively measure DEK protein in the urine of patients suspected of having bladder cancer. The measurement of urine DEK protein, relative to an established cut-off, is correlated with the presence or absence of bladder cancer.

Conditions

Sponsors & Collaborators

  • Medical Diagnostic Laboratories, LLC

    lead INDUSTRY

Principal Investigators

  • Jason Trama, PhD · Medical Diagnostic Laboratories, LLC

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2015-10-01
Completion
2016-10-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01563796 on ClinicalTrials.gov